A multi-effective and long-acting immunotherapy through one single hydrogel based injection.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Cancer recurrence and metastasis remain significant clinical challenges.
• Current immunotherapies often require multiple administrations and can be costly.
• Developing effective, single-administration cancer treatments is a critical need.

Purpose of the Study:

• To develop a dual-modal therapy combining photothermal and immune-stimulatory effects.
• To create a drug-eluting hydrogel system for sustained release of macrophage migration inhibitory factor (MIF) inhibitors.
• To evaluate the efficacy of this combined therapy in inhibiting cancer progression and enhancing anti-tumor immunity.

Main Methods:

• Synthesis and characterization of gold nanorods (AuNRs).
• Fabrication of a hydrogel for sustained release of MIF inhibitors.
• In vitro cellular studies assessing cancer cell proliferation and migration.
• In vivo animal studies evaluating tumor growth inhibition and immune cell infiltration (CD8+ T cells).

Main Results:

• The dual-therapy demonstrated significant inhibition of cancer cell proliferation, migration, and recurrence.
• Photothermal therapy effectively treated localized tumors.
• The hydrogel system successfully released MIF inhibitors, modulating the tumor microenvironment.
• Significant increase in CD8+ T cell infiltration within tumors was observed, indicating enhanced anti-tumor immunity.
• The therapy showed efficacy without the need for multiple injections.

Conclusions:

• The developed dual-effective therapy using AuNRs and a drug-loaded hydrogel offers a promising strategy for cancer treatment.
• This approach effectively suppresses cancer progression and enhances immune response.
• The sustained-release hydrogel system provides a convenient alternative to traditional multiple-injection immunotherapies.